Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 159
Filtrar
1.
Pol J Vet Sci ; 26(4): 621-628, 2023 Dec 12.
Artigo em Inglês | MEDLINE | ID: mdl-38088305

RESUMO

The aim of this study was to evaluate the effect of benign prostatic hyperplasia (BPH) on nitric oxide (NO) production by spermatozoa and sperm parameters in dogs. The study was conducted on 40 intact dogs of various breeds. The dogs were assigned to two groups: BPH group (n=20) and non-affected group (n=20). The sperm concentration and motility parameters of spermatozoa were assessed using computer-assisted sperm analysis. For the assessment of sperm morphology monochromatic Diff-Quick stain was used. Plasma membrane integrity, mitochondrial membrane potential and the spermatozoa producing nitric oxide and with apoptotic-like changes were determined using fluorescent stain methods. The percentages of motile sperm, sperm with progressive motility and normal sperm were statistically significantly (p<0.05) lower in dogs with BPH than in non-affected dogs. The proportion of sperm in motility subcategory RAPID was statistically significantly (p<0.05) lower in dogs with BPH than in control dogs, whereas in the STATIC motility subcategory the proportion was significantly (p<0.05) higher in dogs with BPH. The percentage of spermatozoa producing NO was significantly (p<0.05) higher in dogs with BPH than in control dogs. In conclusion, the results of this study showed that BPH adversely affects semen quality, especially motility, in dogs. The decreased semen quality was associated with an increased proportion of spermatozoa generating NO. Further research is needed to clarify the mechanisms by which BPH affects semen quality.


Assuntos
Doenças do Cão , Hiperplasia Prostática , Preservação do Sêmen , Masculino , Cães , Animais , Análise do Sêmen/veterinária , Sêmen , Hiperplasia Prostática/veterinária , Óxido Nítrico , Motilidade dos Espermatozoides , Espermatozoides , Preservação do Sêmen/veterinária
2.
Pol J Vet Sci ; 26(4): 667-673, 2023 Dec 12.
Artigo em Inglês | MEDLINE | ID: mdl-38088310

RESUMO

The aim of this study was to evaluate the antioxidative/oxidative status of spermatozoa and prostatic fluid in dogs with benign prostatic hyperplasia (BPH) by the determination of total antioxidant capacity and protein peroxidation markers. Study was conducted on 40 intact dogs of various breeds. The dogs were assigned to two groups: BPH group (n=20) and non-affected group (n=20). The second and third fractions of the ejaculate were collected separately by digital manipulation. Total antioxidant capacity (TAC) and the concentrations of SH-groups in sperm and prostatic fluid were determined spectrophotometrically, the concentrations of bityrosine and formylkynurenine were determined using spectrofluorimetric methods. The mean values of TAC in spermatozoa and prostatic fluid were significantly lower (p<0.05), whereas the mean contents of biotyrosine and formylkinurenine were significantly higher (p<0.05) in BPH dogs compared to control dogs. There was no statistically significant difference in the content of SH group between dogs with BPH and control dogs (p>0.05). In conclusion, the results indicate that BPH in dogs is associated with reduced total antioxidant capacity and increased protein oxidation in the prostatic fluid and spermatozoa, and suggest the importance of oxidative stress in the pathogenesis of this condition. The potential role of antioxidants in the prevention and therapy of canine BPH requires further studies.


Assuntos
Doenças do Cão , Hiperplasia Prostática , Cães , Masculino , Animais , Antioxidantes/metabolismo , Hiperplasia Prostática/veterinária , Sêmen/metabolismo , Espermatozoides , Estresse Oxidativo , Doenças do Cão/patologia
3.
BMC Vet Res ; 19(1): 234, 2023 Nov 09.
Artigo em Inglês | MEDLINE | ID: mdl-37946179

RESUMO

BACKGROUND: Prostatic carcinoma (PCA) is a rare but severe condition in dogs that is similar to the androgen-independent form of PCA in men. In contrast to humans, PCA is difficult to diagnose in dogs as reliable biomarkers, available for PCA screening in human medicine, are currently lacking in small animal oncology. Calprotectin (S100A8/A9) and S100A12 are Ca2+-binding proteins of the innate immune system with promising potential to distinguish malignant from benign urogenital tract conditions, similar to the blood neutrophil-to-lymphocyte-ratio (NLR). However, both have not yet been extensively investigated in dogs with PCA. Thus, this study aimed to evaluate the expression of the S100/calgranulins (calprotectin, S100A12, and their ratio [Cal-ratio]) in prostatic biopsies from nine dogs with PCA and compare them to those in dogs with benign prostatic lesions (eight dogs with prostatitis and ten dogs with benign prostatic hyperplasia [BPH]) as well as five healthy controls. In addition, blood NLRs were investigated in twelve dogs with PCA and 22 dogs with benign prostatic conditions. RESULTS: Tissue S100A8/A9+ cell counts did not differ significantly between tissue from PCA and prostatitis cases (P = 0.0659) but were significantly higher in dogs with prostatitis than BPH (P = 0.0013) or controls (P = 0.0033). S100A12+ cell counts were significantly lower in PCA tissues than in prostatitis tissue (P = 0.0458) but did not differ compared to BPH tissue (P = 0.6499) or tissue from controls (P = 0.0622). Cal-ratios did not differ significantly among the groups but were highest in prostatitis tissues and significantly higher in those dogs with poor prostatitis outcomes than in patients that were still alive at the end of the study (P = 0.0455). Blood NLR strongly correlated with prostatic tissue S100A8/A9+ cell counts in dogs with PCA (ρ = 0.81, P = 0.0499) but did not differ among the disease groups of dogs. CONCLUSIONS: This study suggests that the S100/calgranulins play a role in malignant (PCA) and benign (prostatic inflammation) prostatic conditions and supports previous results in lower urinary tract conditions in dogs. These molecules might be linked to the inflammatory environment with potential effects on the inflammasome. The blood NLR does not appear to aid in distinguishing prostatic conditions in dogs. Further investigation of the S100/calgranulin pathways and their role in modulation of tumor development, progression, and metastasis in PCA is warranted.


Assuntos
Doenças do Cão , Hiperplasia Prostática , Neoplasias da Próstata , Prostatite , Masculino , Humanos , Cães , Animais , Complexo Antígeno L1 Leucocitário , Hiperplasia Prostática/veterinária , Prostatite/veterinária , Proteína S100A12 , Neutrófilos/patologia , Neoplasias da Próstata/veterinária , Calgranulina A , Linfócitos , Doenças do Cão/diagnóstico
4.
Open Vet J ; 13(10): 1308-1317, 2023 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-38027403

RESUMO

Background: Prostate disease represents about 0.7% of diseases in canines. The main diagnosed pathology is benign prostatic hyperplasia (BPH). However, the reports that study the association of a certain clinical sign with a specific prostate disease are scarce. Aim: The main objective of this study was to evaluate the clinical relevance of the most commonly observed clinical signs associated with the different prostatic disorders in canines admitted to the hospital of the Facultad de Veterinaria-Universidad de la República between 2011 and 2019. Methods: This retrospective study included 7,729 male canines treated at the hospital de la Facultad de Veterinaria-Universidad de la República (Montevideo, Uruguay) between 2011 and 2019. 289 canines with a presumptive/definitive diagnosis of prostate diseases were selected, recording the presence/absence of associated clinical signs. Results were reported in terms of odds ratios (ORs) using logistic regression (p < 0.05). Results: The five most frequently reported clinical signs were tenesmus (34%), anorexia (32%), lethargy (27%), prostatomegaly or pain during rectal examination (25%), and abdominal pain from palpation (22%). Diarrhea (3.39 vs. 0.33 OR), anorexia (2.07 vs. 0.39 OR), weight loss (2.27 vs. 0.27 OR), hematuria (3.25 vs. 0.44 OR), and urinary incontinence (2.96 vs. 0.33 OR) indicated a highest predictive value (p < 0.05) with prostatitis versus BPH, respectively. Being weight loss, the clinical sign is more frequently associated with neoplasia (20.2 OR, p = 0.002). Conclusion: This study shows that there are clinical signs with a higher degree of association for certain canine prostatic disorders than others.


Assuntos
Doenças do Cão , Hiperplasia Prostática , Masculino , Animais , Cães , Hiperplasia Prostática/diagnóstico , Hiperplasia Prostática/epidemiologia , Hiperplasia Prostática/veterinária , Estudos Retrospectivos , Uruguai/epidemiologia , Anorexia/complicações , Anorexia/veterinária , Redução de Peso , Doenças do Cão/diagnóstico , Doenças do Cão/epidemiologia
5.
Reprod Domest Anim ; 58(8): 1125-1131, 2023 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-37337834

RESUMO

The gonadotropin-releasing hormone (GnRH) stimulation test is used to investigate testicular production of testosterone (T) when performing a breeding soundness examination. In male dogs with fertility problems, the prostate should also be investigated as prostatic conditions may frequently lower semen quality. Serum concentrations of canine prostatic-specific esterase (CPSE) increase in dogs with benign prostatic hyperplasia (BPH). When performing a breeding soundness examination in a male dog, GnRH administration is frequently done at the beginning of the process and then both T and CPSE are assayed on the same serum sample collected 1 h following the GnRH injection. The aim of this study was to assess whether or not the administration of GnRH may alter CPSE concentrations in dogs with a healthy prostate. Twenty-eight client-owned intact adult male dogs were included in the study. Following a 7-day sexual rest all male dogs underwent a clinical examination and an ultrasonographic examination of the prostatic gland. Prostatic size and parenchyma of every tested dog were evaluated by ultrasonography to assess prostatic conditions. Two different GnRH stimulation protocols were used, A = gonadorelin 50µg/dog SC (n = 15) and B = buserelin 0.12 µg/kg IV (n = 13). T and CPSE concentrations were measured before and 1 h after GnRH administration by a laser-induced fluorescence analysis. Buserelin and gonadorelin were equally effective in causing a significant increase in serum T concentrations in the post GnRH sample. When considering the 28 dogs together, CPSE concentrations did not change following the stimulation test with either GnRH compound; however, in 4/28 cases, the post GnRH value was markedly increased to values compatible with a diagnosis of BPH. There was no difference in the action of buserelin or gonadorelin in causing an increase in serum T concentrations. CPSE secretion was increased in approximately 15% of dogs treated with either buserelin or gonadorelin. Therefore, whenever performing diagnostic testing in intact male dogs, CPSE should not be assayed on a post-GnRH serum sample.


Assuntos
Doenças do Cão , Hiperplasia Prostática , Cães , Animais , Masculino , Próstata , Hiperplasia Prostática/diagnóstico , Hiperplasia Prostática/veterinária , Esterases , Análise do Sêmen/veterinária , Busserrelina , Testosterona
6.
Theriogenology ; 198: 356-360, 2023 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-36640740

RESUMO

Prostatic hyperplasia (PH) is an androgen-dependent condition associated with increased prostatic size that is common in intact dogs, and similar to the condition in men. In dogs, the increase in prostatic size is most prominent the first years, and after approximately four years (in beagles), a plateau is reached, and further growth is slower. Why the prostate continues to grow more in some individuals is not clear. Most testosterone in the circulation is bound to albumin or sex hormone binding globulin (SHBG) and only a minor part is unbound and biologically active. The binding to SHBG has higher affinity than that to albumin. In addition, SHBG has own biological functions, modifying testosterone action. The aim of the present study was to investigate if there is an association between relative prostatic size and the variables total testosterone concentration, SHBG concentration, an estimation of bioavailable testosterone: the ratio between testosterone and SHBG (free androgen index, FAI), estradiol concentration, the estradiol/testosterone ratio, dog age and dog weight. Hormone concentrations were measured in serum from 79 intact male dogs aged ≥ four years, weighing ≥ five kg. The size of the prostate was estimated using ultrasonography, and relative prostate size, Srel, was calculated as the estimated size related to the normal size for a 4-year-old dog of the same weight. There as a negative correlation between testosterone concentration and age (ρ = -0.27, P = 0.018) and a positive correlation between age and Srel (ρ = 0.27, P = 0.016) and between SHBG and weight (ρ = 0.38, P = 0.001). The FAI was negatively correlated with dog weight (ρ = -0.32, P = 0.004). There were no significant correlations between Srel and SHBG or FAI or between estradiol or estradiol/testosterone and Srel, age or weight. A multiple regression analysis showed significant associations between log Srel and log testosterone concentration, log age and log weight of the dog, with an adjusted R2 of 9.5%. Although the variables total testosterone concentration, age and weight of the dog were all significantly associated with Srel, the coefficient of determination was low, indicating that they only explained a minor part of the prostatic size. The results support the analysis of total testosterone in studies of prostatic growth in the dog.


Assuntos
Doenças do Cão , Hiperplasia Prostática , Masculino , Cães , Animais , Testosterona , Androgênios , Estradiol , Hiperplasia Prostática/veterinária , Próstata
7.
Anim Reprod Sci ; 247: 107096, 2022 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-36279818

RESUMO

In small animal practice, prostatic diseases are increasingly encountered. All dogs may experience prostatic disease, but there should be particular attention to breeding dogs, as prostatic disease may decrease semen quality and fertility. The most common prostatic disease is benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the gland affecting intact adult dogs, part of an aging process, including both an increase in cell numbers (hyperplasia) and in cell size (hypertrophy). Acute and chronic prostatitis, prostatic abscess, prostatic neoplasia and prostate squamous metaplasia also occur in dogs, in order of frequency. These diseases often lack pathognomonic clinical signs; therefore, a thorough clinical examination and a correct diagnostic protocol are essential to determine the most appropriate treatment or prophylaxis. Frequently dogs with BPH are asymptomatic, but when clinical signs are present, the most common is a serous to sanguineous urethral discharge. BPH therapy includes various options and is usually recommended when mild-severe signs are present or if clinical signs disturb the dog. In most dogs with this disorder, it is possible to maintain fertility by avoiding castration and choosing alternative therapeutic approaches.


Assuntos
Doenças do Cão , Hiperplasia Prostática , Masculino , Cães , Animais , Hiperplasia Prostática/diagnóstico , Hiperplasia Prostática/veterinária , Hiperplasia Prostática/tratamento farmacológico , Análise do Sêmen/veterinária , Doenças do Cão/terapia , Doenças do Cão/tratamento farmacológico , Orquiectomia/veterinária , Fertilidade
8.
Theriogenology ; 192: 9-13, 2022 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-36030614

RESUMO

Prostatic hyperplasia (PH) is the most common reproductive disorder in dogs and can lead to discomforting problems such as haematuria, urinary incontinence, constipation, difficulty in defecating and stiffness of the hind limbs. The diagnosis of PH is nowadays based on digital rectal examination (DRE), ultrasonography (US) and radiography (X-ray). However, markers associated with PH are barely used for diagnostic purposes. Recently, there have been reports on the use of certain biomarkers for diagnosing PH in dogs such as canine PSA (Prostate Specific Antigen), microRNA and vascular endothelial growth factor (VEGF). Nevertheless, it has been generally accepted that these biomarkers play only an auxiliary role. Accordingly, the aim of our study was to evaluate the usefulness of the CCL11 (eotaxin-1) and TGF-beta 1 markers, which are used in the diagnosis of prostate diseases in humans, in case of dogs with PH. The study was carried out on 40 dogs of different breeds divided into three groups. Group I (n = 9) comprised dogs up to 5 years of age without changes indicative of PH. Group II (n = 17) included dogs aged 5-10 that were examined and diagnosed with (PH) and Group III (n = 14) which consisted of dogs over 10 years of age who were also diagnosed with PH. The study demonstrated that CCL11 levels did not differ significantly between the study groups and the median levels were 7.27 pg/mL, 7.57 pg/mL, 6.81 pg/mL, and IQR ranges 1.55 pg/mL, 1.74 pg/mL, 2.32 pg/mL, respectively. In contrast, TGF-beta 1 levels were detectable only in 6 dogs of group III and averaged the median of 28.86 pg/mL, IQR ranges 10.07 pg/mL. The study proved that CCL11 and TGF-beta 1 markers are of a limited use when diagnosing PH in dogs as no significant correlation related to age, body weight or prostate size was found.


Assuntos
Doenças do Cão , MicroRNAs , Hiperplasia Prostática , Animais , Biomarcadores , Quimiocina CCL11 , Doenças do Cão/diagnóstico , Doenças do Cão/patologia , Cães , Humanos , Hiperplasia/patologia , Hiperplasia/veterinária , Masculino , Próstata/patologia , Antígeno Prostático Específico , Hiperplasia Prostática/diagnóstico , Hiperplasia Prostática/patologia , Hiperplasia Prostática/veterinária , Fator A de Crescimento do Endotélio Vascular
9.
Theriogenology ; 189: 150-157, 2022 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-35760026

RESUMO

This work analysed the expression of prostate polysaccharides in rats with age-related benign prostatic hyperplasia (BPH) for a better understanding of the possible relationship between prostate polysaccharides secretion and BPH onset. For this, prostatic glands from 1 month-old, 3 months-old, 6 months-old and 12 months-old Sprague-Dawley rats were processed in order to identify their overall polysaccharide content. Additionally, serum testosterone was also determined. One-month old rats showed significantly (P < 0.05) lower testosterone levels (0.77 ng/mL±0.12 ng/mL) compared with the other groups, which showed no significant difference among them. PAS staining showed positive polysaccharides markings in both the prostatic lumen and inside of luminal prostatic cells in all groups. Semiquantitative analysis of intraluminal PAS showed that one month-old rats had significantly (P < 0.005) lower PAS intensity when compared with all other groups (100.0 ± 0.5, arbitrary units vs. 107.3 ± 0.6, arbitrary units in 3 months-old ones), whereas 12 months-old ones showed significantly (P < 0.005) higher values when compared with all other groups (133.6 ± 3.5, arbitrary units in 12 months-old rats vs. 108.6 ± 1.4, arbitrary units in 6 months-old ones). The PAS + content practically disappeared when tissues were pre-incubated with either α-amylase or amyloglucosidase, regardless of a previous incubation with proteinase K. Incubation of prostate extracts from 12 months-old rats for 2 h with α-amylase yielded a significantly higher amount of free glucose (1.47 nmol/mg protein±0.23 nmol/mg protein vs. 0.32 nmol/mg protein±0.01 nmol/mg protein in untreated extracts). Similar results were obtained when extracts were pre-incubated with amyloglucosidase. Contrarily, pre-incubation with N-glycosidase induced a significantly (P < 0.05), much lower increase of free glucose. Pre-treatment with proteinase K did not significantly modify these results, which indicate that BPH is related to an increase in the secretion of low ramified ductal α-glycosydic polysaccharides that were not protected against lysis by any type of protein protective core. These changes seem to not be related with concomitant variations in serum testosterone levels.


Assuntos
Hiperplasia Prostática , Doenças dos Roedores , Animais , Endopeptidase K/metabolismo , Glucana 1,4-alfa-Glucosidase/metabolismo , Glucose/metabolismo , Hiperplasia/metabolismo , Hiperplasia/patologia , Hiperplasia/veterinária , Masculino , Extratos Vegetais/farmacologia , Polissacarídeos , Próstata/patologia , Hiperplasia Prostática/patologia , Hiperplasia Prostática/veterinária , Ratos , Ratos Sprague-Dawley , Doenças dos Roedores/metabolismo , Doenças dos Roedores/patologia , Testosterona , alfa-Amilases/metabolismo
10.
Reprod Domest Anim ; 57(2): 157-164, 2022 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-34724270

RESUMO

The objective of this study was to evaluate the effect of castration on dimensions of the prostate by B-mode ultrasound for 90 days, as well as to evaluate changes in serum concentrations of testosterone and oestradiol in clinically healthy canines and those with benign prostatic hyperplasia (BPH). Three groups of animals were used: healthy canines castrated on day 0 (HCC, n = 8), canines with a diagnosis of benign prostatic hyperplasia (BPHC, n = 9) castrated on day 0 and healthy uncastrated canines (IHCC, n = 10). Prostate size was obtained by B-mode ultrasound, while blood samples were collected (days 0, 7, 14, 28, 60 and 90 post-castration) to determine the serum testosterone and oestradiol concentration. Castration did not affect serum oestradiol concentrations. Castration led to a decrease in serum testosterone (reaching values <20 ng/dl in the first week, p < .05), causing a gradual decrease in dimensions of prostate parameters relative to body weight (p < .05). Canines with BPHC had similar prostate dimensions as the IHCC group 2 weeks post-castration. In relation to the prostate's relative parameters, the decrease with time was greater in canines with BPHC than those in the HCC group. When evaluating parameters as a percentage of relative change, the decrease with time was similar in both castrated groups, except for relative length percentage, which presented a more pronounced decline in BPHC canines than HCC canines. In conclusion, castration is an effective, fast and long-lasting treatment for canine patients with BPH, as it causes a rapid decrease in blood testosterone concentrations and a decrease in glandular volume, but does not affect serum oestradiol concentrations. This study did not determine the mechanisms of action, but allowed us to observe (based on morphometric variables) that characteristics of prostate involution after castration differed between canines with BPH and healthy canines.


Assuntos
Carcinoma Hepatocelular , Doenças do Cão , Neoplasias Hepáticas , Hiperplasia Prostática , Animais , Carcinoma Hepatocelular/veterinária , Cães , Neoplasias Hepáticas/veterinária , Masculino , Orquiectomia/veterinária , Próstata , Hiperplasia Prostática/veterinária , Testosterona
11.
Reprod Domest Anim ; 57(1): 72-79, 2022 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-34706118

RESUMO

Benign prostatic hyperplasia (BPH) may alter prostatic fluid biochemical composition causing reduced fertility. Osaterone acetate (OA) is an androgen receptor antagonist marketed for treatment of canine BPH. Little information exists on effects of OA administration on biochemical composition of canine prostatic fluid and its role on fertility. The aim of this research was to study biochemical composition of prostatic fluid and its role on semen quality in dogs with BPH undergoing treatment with OA. Eight intact, 5-11-year-old dogs with benign prostatic hyperplasia were treated orally with OA at a dose of 0.25-0.5 mg/kg once daily for seven days. Prostatic volume, semen evaluation and a biochemical analysis of prostatic fluid were performed on the day before treatment (D0), D60, D120, D180 and D240. A significant reduction (57% and 61%) of prostatic volume was observed at D60 and D120, respectively, and a significant reduction (20%) of normal spermatozoa was observed at D60 coincident with a significant increase of sperm tail defects, which disappeared during the course of the treatment. Prostatic fluid composition did not vary during the OA treatment except for zinc (Zn2+ ) with a significant increase at D120 and D180 correlated with the return to normal sperm values. In conclusion, canine Zn2+ prostatic fluid concentrations decrease during development of BPH and return to normal during treatment with OA. Zn2+ is an important electrolyte for semen quality, suggesting that oral Zn2+ supplementation might be considered a treatment to improve semen quality.


Assuntos
Doenças do Cão , Hiperplasia Prostática , Animais , Acetato de Clormadinona/análogos & derivados , Doenças do Cão/tratamento farmacológico , Cães , Masculino , Hiperplasia Prostática/tratamento farmacológico , Hiperplasia Prostática/veterinária , Análise do Sêmen/veterinária
12.
J Am Vet Med Assoc ; 259(10): 1154-1162, 2021 11 15.
Artigo em Inglês | MEDLINE | ID: mdl-34727073

RESUMO

OBJECTIVE: To describe the procedure of prostatic artery embolization (PAE) in dogs with prostatic carcinoma and to evaluate the short-term outcome for treated dogs. ANIMALS: 20 client-owned dogs with prostatic carcinomas between May 2014 and July 2017. PROCEDURES: In this prospective cohort study, dogs with carcinoma of the prostate underwent PAE with fluoroscopic guidance. Before and after PAE, dogs underwent CT and ultrasonographic examinations of the prostate, and each owner completed a questionnaire about the dog's clinical signs. Results for before versus after PAE were compared. RESULTS: Prostatic artery embolization was successfully performed in all 20 dogs. Tenesmus, stranguria, and lethargy were significantly less common 30 days after PAE (n = 2, 1, and 0 dogs, respectively), compared with before PAE (9, 10, and 6 dogs, respectively). Median prostatic volume was significantly less 30 days after PAE (14.8 cm3; range, 0.4 to 48.1 cm3; interquartile [25th to 75th percentile] range, 6.7 to 19.5 cm3), compared with before PAE (21.7 cm3; range, 2.9 to 77.7 cm3; interquartile range, 11.0 to 35.1 cm3). All dogs had a reduction in prostatic volume after PAE, with a median prostatic volume loss of 39.4% (95% CI, 20.3% to 59.3%). CONCLUSIONS AND CLINICAL RELEVANCE: Prostatic artery embolization was associated with decreased prostate volume and improved clinical signs in this cohort. The short-term response to PAE appears promising, and evaluation of the long-term impact on survival time is needed.


Assuntos
Carcinoma , Doenças do Cão , Embolização Terapêutica , Hiperplasia Prostática , Animais , Artérias , Carcinoma/veterinária , Doenças do Cão/diagnóstico por imagem , Doenças do Cão/terapia , Cães , Embolização Terapêutica/veterinária , Masculino , Estudos Prospectivos , Hiperplasia Prostática/terapia , Hiperplasia Prostática/veterinária , Resultado do Tratamento
13.
Theriogenology ; 171: 113-118, 2021 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-34058504

RESUMO

Numerous specific biomarkers with a prognostic and diagnostic value comparable to histopathological findings are now used for non-invasive diagnosis of prostate diseases in humans. Meanwhile, as far as dogs are concerned, the diagnosis of prostate disorders is based solely on clinical examination and ultrasound (USG). Therefore, the aim of the study was to assess the usefulness of two biomarkers, i.e. miRNA-129 and VEGF for the diagnosis of BPH in dogs. The study involved 40 dogs divided into three groups. Group I (n = 9) comprised healthy dogs up to the age of 5 years, Group II (n = 17) comprised dogs between the ages of 5-10 suffering from BPH as confirmed by the examination and Group III (n = 14) comprising dogs over 10 years of age, which also had BPH confirmed. The results demonstrated that dogs in group II and III exhibited a significant decrease in miRNA expression (P < 0.0001) and a significant increase in serum VEGF levels (P = 0.025) when compared to the dogs in group I. There was also a positive correlation between the prostate size and VEGF level. The findings led to the conclusion that the determination of miRNA-129 and VEGF can significantly contribute to the diagnosis of prostate disorders in dogs.


Assuntos
Doenças do Cão , MicroRNAs , Hiperplasia Prostática , Animais , Biomarcadores , Doenças do Cão/diagnóstico , Doenças do Cão/genética , Cães , Humanos , Masculino , MicroRNAs/genética , Hiperplasia Prostática/diagnóstico , Hiperplasia Prostática/genética , Hiperplasia Prostática/veterinária , Fator A de Crescimento do Endotélio Vascular/genética , Fatores de Crescimento do Endotélio Vascular
14.
Vet Med Sci ; 7(5): 1493-1503, 2021 09.
Artigo em Inglês | MEDLINE | ID: mdl-34015193

RESUMO

Serum concentrations of prolactin (PRL), insulin-like growth factor-1 (IGF-1) and 25 hydroxyvitamin D3 (25-OHD3 ) were analysed to investigate their possible involvement in the pathogenesis of benign prostatic hyperplasia (BPH). For this, dogs of the Rhodesian Ridgeback (RR) breed were used because of a verified breed disposition for the development of BPH. Labrador Retrievers (LR) served as controls. The prostate gland status was characterised by the prostate gland volume, clinical signs of BPH (haemospermia and sonographic findings) and the plasma concentration of canine prostate-specific arginine esterase (CPSE). Breed specificity in the RR was expressed by a correlation of PRL with breed (p < 0.05). Similar relationships existed in the dogs with normal CPSE (CPSEn) with respect to the IGF-1 concentrations (LR: p < 0.05). The latter were negatively correlated with prostatic volume and age (both p < 0.05). Concentrations of 25-OHD3 were tendentially (p = 0.18) lower in the RR with increased CPSE (CPSEi) compared with the CPSEn LR and RR showing clinical signs of BPH. A negative correlation between serum 25-OHD3 and age (p < 0.05) existed in the CPSEi RR. Proof of 25-OHD3 in prostatic secretion proved to be a breed specific feature in the RR (p < 0.0001). For all RR dogs showing clinical signs of BPH, a close to significant (p = 0.06) positive correlation with prostate gland volume was found. The results of the present study reveal no clear hints towards the significance of PRL and IGF-1 in the pathogenesis of canine BPH. In the RR breed there were indications of a causal relationship with age-dependent changes in the vitamin D metabolism. The data suggest the possibility of preventing or treating canine BPH by administering vitamin D or substances involved in the intraprostatic vitamin D metabolism.


Assuntos
Doenças do Cão , Hiperplasia Prostática , Animais , Calcifediol/uso terapêutico , Doenças do Cão/diagnóstico , Cães , Fator de Crescimento Insulin-Like I , Masculino , Prolactina/uso terapêutico , Hiperplasia Prostática/diagnóstico , Hiperplasia Prostática/veterinária , Vitamina D/análogos & derivados
15.
BMC Vet Res ; 17(1): 173, 2021 Apr 26.
Artigo em Inglês | MEDLINE | ID: mdl-33902583

RESUMO

BACKGROUND: Enlargement of the prostate is associated with prostatic diseases in dogs, and an estimation of prostatic size is a central part in the diagnostic workup. Ultrasonography is often the method of choice, but biomarkers constitute an alternative. Canine prostate specific esterase (CPSE) shares many characteristics with human prostate specific antigen (PSA) and is related to prostate size. In men with clinical symptoms of prostatic disease, PSA concentrations are related to prostate growth. The aims of the present follow-up study were to evaluate if the concentration of CPSE is associated with future growth of the prostate, and if analysis of a panel of 16 steroids gives further information on prostatic growth. Owners of dogs included in a previous study were 3 years later contacted for a follow-up study that included an interview and a clinical examination. The prostate was examined by ultrasonography. Serum concentrations of CPSE were measured, as was a panel of steroids. RESULTS: Of the 79 dogs included at baseline, owners of 77 dogs (97%) were reached for an interview, and 22 were available for a follow-up examination. Six of the 79 dogs had clinical signs of prostatic disease at baseline, and eight of the remaining 73 dogs (11%) developed clinical signs between baseline and follow-up, information was lacking for two dogs. Development of clinical signs was significantly more common in dogs with a relative prostate size of ≥2.5 at baseline (n = 20) than in dogs with smaller prostates (n = 51). Serum concentrations of CPSE at baseline were not associated with the change in prostatic size between baseline and follow-up. Serum concentrations of CPSE at baseline and at follow-up were positively associated with the relative prostatic size (Srel) at follow-up. Concentrations of corticosterone (P = 0.024), and the class corticosteroids (P = 0.0035) were positively associated with the difference in Srel between baseline and follow-up. CONCLUSIONS: The results support the use of CPSE for estimating present and future prostatic size in dogs ≥4 years, and the clinical usefulness of prostatic size for predicting development of clinical signs of prostatic disease in the dog. The association between corticosteroids and prostate growth warrants further investigation.


Assuntos
Esterases/sangue , Próstata/enzimologia , Hiperplasia Prostática/veterinária , Animais , Biomarcadores/sangue , Doenças do Cão/diagnóstico , Doenças do Cão/enzimologia , Cães , Seguimentos , Masculino , Próstata/diagnóstico por imagem , Hiperplasia Prostática/diagnóstico por imagem , Hiperplasia Prostática/enzimologia , Esteroides/sangue , Ultrassonografia/veterinária
16.
Acta Vet Hung ; 69(1): 9-13, 2021 04 10.
Artigo em Inglês | MEDLINE | ID: mdl-33844640

RESUMO

The present case report describes the clinical signs and case resolution of an intact 9-year-old male crossbreed dog with spontaneous constipation. The dog presented with abdominal pain, lack of appetite, tenesmus and without signs of defecation in the last 4 days. No important alterations were observed in the complete blood count and biochemistry. A substantial obstruction caused by a faecaloma and a prostate with increased size was observed on X-rays. Benign prostatic hyperplasia (BPH) was confirmed by ultrasonography (size: 48.29 cm3) and by testing the serum canine prostate-specific arginine esterase concentration (105.97 ng/mL). Colon impaction was resolved with rectal enemas within two days. BPH was treated with osaterone acetate. Ultrasonographic checks were performed after 60 and 180 days from the demission and a concrete constant reduction of prostatic volume and of the clinical signs was established. Faecaloma is an uncommon finding in male dogs, and it occurs especially as a consequence of BPH. Colon impaction in patients with BPH is usually subclinical, but it is important to underline how, in severe cases, perforation of the colon and faecal peritonitis can occur, leading to fatal conditions for the animal. In conclusion, prostatic enlargement should always be considered in male dogs suffering from colonic impaction.


Assuntos
Doenças do Cão , Hiperplasia Prostática , Animais , Colo , Doenças do Cão/diagnóstico , Doenças do Cão/etiologia , Cães , Masculino , Hiperplasia Prostática/complicações , Hiperplasia Prostática/veterinária , Ultrassonografia
17.
J Comp Pathol ; 182: 43-53, 2021 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-33494907

RESUMO

Benign prostatic hyperplasia (BPH) is common in aged dogs, but the pathogenesis has not been clearly elucidated. A total of 33 male Iranian dogs of mixed breed and in three age groups (under 3 years [n = 10]; 3-6 years [n = 15]; over 6 years [n = 8]), were investigated. BPH was confirmed by ultrasonography and histopathology in 13 cases. The highest prevalence of BPH was in the 3-6 years age group (8/15; 53.3%). Examination of sections of prostate that had been stained with Masson's trichrome revealed that the intensity of stromal smooth muscle cell staining (P <0.05) and the number of fibroblasts (P = 0.002) were significantly increased in BPH compared with normal prostate glands. Prostate cells from dogs with BPH (n = 13) had a significantly higher intensity of cytoplasmic immunolabelling with antibodies against glial cell line-derived neurotrophic factor (GDNF), cytokeratin (CK) AE1/AE3, vimentin, fibroblast growth factor-1 (FGF-1) and prostate-specific antigen (PSA), compared with normal prostate glands (n = 20) (P = 0.001), except for PSA, which was negative in both normal and BPH affected prostates. The overexpression of GDNF and FGF-1 in stromal and epithelial cells of prostate glands of dogs with BPH suggests that GDNF has a paracrine or autocrine role in stimulating cellular proliferation. GDNF overexpression may also play a pathogenetic role in promoting chronic prostatitis and increasing fibrosis and the smooth muscle component of the prostate gland in BPH.


Assuntos
Doenças do Cão , Fator 1 de Crescimento de Fibroblastos/genética , Fator Neurotrófico Derivado de Linhagem de Célula Glial/genética , Hiperplasia Prostática , Animais , Doenças do Cão/genética , Cães , Irã (Geográfico) , Masculino , Hiperplasia Prostática/genética , Hiperplasia Prostática/veterinária
18.
Top Companion Anim Med ; 42: 100501, 2021 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-33249242

RESUMO

Ultrasonography is one of the most common methods for the diagnosis of prostate disorders, such as benign prostatic hyperplasia (BPH), in dogs. Changes in the echotexture are one of the indicators used to diagnose prostate disorders. The purpose of this study was to investigate the changes occurred in the dogs' prostate echotexture during the induction of BPH using image analysis. Twenty sexually mature male intact mixed-breed dogs were selected and divided randomly into control and BPH-induced groups. BPH was induced using testosterone and estrogen injections for 63 days. The ultrasound imaging of the dogs' prostate was performed during the induction of BPH on days 0, 21, 42, and 63. The echotexture of the prostate parenchyma was analyzed using the Image J software. Then, the changes in the echotexture and its correlation and linear regression with the prostate volume and canine prostate specific esterase (CPSE) concentration were evaluated by statistical tests. The prostate parenchyma echotexture did not show any significant changes during the induction of BPH and in comparison with that of the control group. While prostate volume and CPSE concentration increased significantly, indicating that BPH was induced in the dogs. There was no significant correlation and linear regression between the prostate echotexture and prostate volume or between the CPSE concentration and prostate echotexture. According to the results, the alteration in the prostate parenchymal echotexture did not occur in the early stages of induced BPH, but significant changes occurred in the prostate volume and CPSE concentration during those early stages.


Assuntos
Doenças do Cão/patologia , Esterases/sangue , Próstata/enzimologia , Hiperplasia Prostática/diagnóstico por imagem , Ultrassonografia/métodos , Animais , Biomarcadores/sangue , Doenças do Cão/enzimologia , Cães , Masculino , Tamanho do Órgão , Hiperplasia Prostática/patologia , Hiperplasia Prostática/veterinária , Ultrassonografia/veterinária
19.
Vet Med Sci ; 7(1): 35-40, 2021 01.
Artigo em Inglês | MEDLINE | ID: mdl-32881401

RESUMO

In the last years, the need to look for an accurate and precise diagnosis of prostatic diseases in dogs has grown. Among other diagnostic tools, the seric CPSE has been studied and identified as a valid and specific biomarker for prostatic disorders, since it can result significantly more elevated in dogs affected by several prostatic abnormalities, such as benign prostatic hyperplasia, bacterial prostatitis and prostatic carcinoma. Therefore, dosing CPSE in serum represents a new diagnostic and screening tool. Dosing CPSE in everyday clinical practice has three objectives: (a) the diagnosis of benign prostatic hyperplasia; (b) the preventive screening of prostatic disorders in healthy dogs; (c) the medical follow-up in subjects with prostatic disorders during and after medical therapy. Neither circadian rhythms nor transrectal palpation performed during the andrological examination do affect CPSE. A sexual rest of at least 24 hr before dosing CPSE is recommended as it is affected by ejaculation.


Assuntos
Carcinoma/veterinária , Testes Diagnósticos de Rotina/veterinária , Doenças do Cão/diagnóstico , Esterases/metabolismo , Neoplasias dos Genitais Masculinos/veterinária , Hiperplasia Prostática/veterinária , Prostatite/veterinária , Andrologia , Animais , Biomarcadores , Carcinoma/diagnóstico , Carcinoma/enzimologia , Doenças do Cão/enzimologia , Cães , Neoplasias dos Genitais Masculinos/diagnóstico , Neoplasias dos Genitais Masculinos/enzimologia , Masculino , Próstata/química , Hiperplasia Prostática/diagnóstico , Hiperplasia Prostática/enzimologia , Prostatite/diagnóstico , Prostatite/enzimologia
20.
Domest Anim Endocrinol ; 75: 106601, 2021 04.
Artigo em Inglês | MEDLINE | ID: mdl-33333452

RESUMO

Benign prostatic hyperplasia (BPH) is a disorder related to hormone imbalance, local angiogenesis, and prostate growth, which can be treated surgically (orchiectomy) or medically (most commonly with finasteride). However, finasteride therapy is not completely established in dogs regarding local action and posology. This study aimed to evaluate the effect of different doses of finasteride and orchiectomy on hormonal profile, prostate apoptosis, blood flow, and biometry in dogs with BPH. Dogs were assigned to the following groups: untreated, 0.1 mg, 0.2 mg, and 0.5 mg/kg/d of finasteride and orchiectomy. All dogs were assessed monthly: day 0 (before treatment), day 30, and day 60 and subjected to prostate B-mode and Doppler ultrasonography and hormonal analysis (testosterone and dihydrotestosterone). After 60 d, prostatic biopsy was performed for histology and immunohistochemical evaluation for apoptosis (caspase-3). On day 60, percentage reduction of prostatic volume was greater in orchiectomized dogs than that in finasteride groups, which, conversely, was greater than untreated dogs. On day 60, 0.2-mg finasteride, 0.5-mg finasteride, and orchiectomy groups had higher prostatic blood flow than 0.1-mg finasteride and untreated groups. In addition, both 0.5-mg finasteride and orchiectomy groups had an increase in prostate artery resistance. Orchiectomy significantly decreased androgen concentrations at 30 d onward, differing from the remaining groups. The orchiectomy group had lower caspase-3 immunostaining, however, not different from untreated and 0.5-mg finasteride. In conclusion, 0.5 mg/kg finasteride promoted more effective prostate apoptosis and hemodynamic effects among medical treatments, whereas orchiectomy caused prostate atrophy and sharp endocrine changes in dogs with BPH.


Assuntos
Doenças do Cão , Hiperplasia Prostática , Animais , Di-Hidrotestosterona , Doenças do Cão/tratamento farmacológico , Cães , Finasterida/farmacologia , Finasterida/uso terapêutico , Masculino , Próstata/patologia , Hiperplasia Prostática/tratamento farmacológico , Hiperplasia Prostática/veterinária , Testosterona/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...